Major US Manufacturers and Product Lines

As of October 2026, four companies make the prescription continuous glucose monitors (CGMs) sold in the US: Dexcom, Abbott, MiniMed and Senseonics. Dexcom and Abbott also sell over-the-counter versions. For most readers, the useful differences aren't the brand names. They're how long a sensor lasts, whether it sits on the skin or is implanted under it, and which insulin pumps it can talk to.

How the market splits

The only revenue split we found from a manufacturer comes from Senseonics, the smallest of the four. Its November 2025 investor presentation, citing an outside market report from October 2025, put 2024 CGM revenue at 56.2% for Abbott, 34.9% for Dexcom, 8.7% for Medtronic and under 1% for Senseonics [1]. Read those numbers with care. They come from a competitor's slide, and that slide sits beside a global market figure without saying whether the split is for the US alone.

Dexcom: G7, G7 15 Day and the end of the G6

Dexcom sells two prescription sensors as of October 2026. The Dexcom G7 lasts 10 days and is cleared for ages 2 and up, while the Dexcom G7 15 Day lasts 15 days and is for adults 18 and older [2][3]. Each adds a 12-hour grace period, which is extra time to put on a new sensor after the old one stops. Warm-up, the wait before the first reading, is 30 minutes for the G7 and 60 minutes for the G7 15 Day [2].

The Dexcom G6, which the G7 sensors replaced, is being phased out. Dexcom says it will no longer manufacture the G6 after July 1, 2026. Pharmacies may still have supplies for a while, but Dexcom doesn't guarantee it [4]. The company is steering G6 users toward a G7 or G7 15 Day and asks them to talk with their doctor about a new prescription [4].

Both Dexcom sensors pair with insulin pumps. Dexcom lists the G7 15 Day for adults on the iLet Bionic Pancreas, Omnipod 5, Tandem Mobi and t:slim X2, and the 10-day G7 for children on those same systems [4]. One Dexcom FAQ still calls Tandem support "in progress," but Tandem's own page says both of its pumps now work with the G7 15 Day [5].

Abbott: FreeStyle Libre 3 Plus and 2 Plus

Abbott's current prescription sensors are the FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus. The FDA cleared both in a single 510(k), and each can be worn for up to 15 days [6]. The same FDA summary calls them integrated CGMs (iCGMs), the FDA category for sensors built to feed readings to other devices, including automated insulin dosing (AID) systems [6].

That was the real change from the sensors they replaced. According to the FDA document, the older Libre 2 and Libre 3 sensors must not be used with AID [6]. Abbott sold those sensors only through September 30, 2025, and anyone moving to a Plus sensor needs a new prescription [7]. The Plus sensors are also cleared down to age 2, compared with age 4 for the older ones [7].

Under the plastic, the FreeStyle Libre line grew out of Abbott's "wired enzyme" chemistry [8]. In the Libre sensor, the glucose-reacting enzyme and a helper molecule called a mediator (an osmium complex) are crosslinked together in a polymer, and the mediator shuttles electrons from the enzyme to the electrode [9]. That work led to the first factory-calibrated CGM, meaning one that doesn't ask the user for fingerstick calibrations [8].

Here's what surprised us: Abbott also builds a sensor for a rival's pumps. In December 2025, Medtronic, whose diabetes business is now MiniMed, began the US launch of the MiniMed 780G system with the Instinct sensor, "made by Abbott," and described Instinct as designed exclusively for MiniMed systems [10].

MiniMed: four sensors, mostly tied to its own systems

MiniMed is the diabetes business Medtronic split off into its own public company. Its shares began trading on Nasdaq on March 6, 2026, and Medtronic owned about 90% of the stock when the offering closed [11]. Older articles and labeling use the Medtronic name for the same products.

MiniMed's comparison page lists four sensors as of October 2026 [12]:

Simplera is the odd one out. The FDA approved it in July 2024 as a standalone real-time CGM for adults that needs no calibration [13]. MiniMed pairs it with the MiniMed Go system and the InPen smart insulin pen rather than with a pump [12]. The other three sensors work only with MiniMed's own systems.

The newest MiniMed pump, the MiniMed Flex, is the company's first app-controlled pump. It went on sale in the US on June 17, 2026, launching with the Simplera Sync sensor [14]. Older MiniMed sensors, including the Guardian Sensor 3 and the Guardian Connect system, no longer appear on the comparison page [12].

Senseonics: the implanted Eversense 365

Senseonics takes a different route. A healthcare provider inserts the Eversense 365 sensor under the skin, and the user wears a smart transmitter over it [15]. Instead of an enzyme, the sensor carries a fluorescent indicator that glows more brightly when glucose binds to it, and the system measures that change in light [15]. The FDA cleared it in September 2024 for up to 1 year of wear in adults 18 and older, as an iCGM that can send readings to AID systems [15]. For more on how this works, see our page on implantable long-term CGM solutions.

The Eversense 365 succeeded the Eversense E3, a 180-day sensor the FDA approved in February 2022 [16]. It still needs fingerstick calibrations, mostly once a week after day 14, according to Senseonics [17]. Since January 1, 2026, Senseonics has handled US sales of Eversense itself, taking over from Ascensia Diabetes Care, and the first patients have started using the Eversense 365 with Sequel's twiist AID system [17]. In its investor pitch, Senseonics lists the common CGM frustrations it wants to address, among them sensor lifetime, wasted sensors and skin irritation [1].

Which sensors work with which pumps

Pump makers publish their own compatibility lists. As of October 2026, they read like this:

• Omnipod 5 (Insulet): Dexcom G7 for ages 2 and up, Dexcom G7 15 Day for adults, FreeStyle Libre 3 Plus and FreeStyle Libre 2 Plus. Insulet says it will keep supporting the G6 while that sensor remains available [18].
• Tandem t:slim X2 with Control-IQ+: Dexcom G7, Dexcom G7 15 Day, FreeStyle Libre 2 Plus and FreeStyle Libre 3 Plus. The Tandem Mobi also works with the G7 15 Day [5].
• Beta Bionics iLet Bionic Pancreas: Dexcom G7, Dexcom G7 15 Day and FreeStyle Libre 3 Plus [4][19].
• twiist AID System: FreeStyle Libre 3 Plus and Eversense 365 [20].
• MiniMed 780G and MiniMed Flex: MiniMed's own sensors, as in the table above [12].

Which pump and sensor fit a given person is a decision to make with their care team. Our article on interoperability with automated insulin delivery explains how these pairings are regulated.

Over-the-counter CGMs

Dexcom and Abbott both sell CGMs that need no prescription. The FDA cleared Dexcom's Stelo on March 5, 2024, as the first over-the-counter CGM, for adults 18 and older who don't use insulin [21]. A Stelo sensor lasts up to 15 days and shows readings every 15 minutes in a phone app. The FDA said it isn't meant for people with problematic hypoglycemia, because it isn't designed to alert users to lows [21]. Abbott's Lingo, cleared in May 2024, is for the same adults; its sensor lasts up to 14 days and the app gives no glucose alerts [22]. Our over-the-counter CGM market page goes further into both.

What we're still watching

The next product to watch is Abbott's Libre Duo 10 Day. In August 2026, the FDA granted it as a prescription sensor that tracks ketones as well as glucose, for people 2 and older, and created a new device category for it in the process [23]. When it reaches US pharmacies is still an open question. So is how long remaining G6 stock lasts now that Dexcom has stopped making it [4].